Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDP-133 vs Lumigan in Open Angle Glaucoma or Ocular Hypertension
NCT03927443Phase 3Withdrawn
- Sponsor
- Sun Pharma
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of SPARC0913 in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Sun Pharma. Primary endpoint: Mean Intra-ocular pressure (study eye) at 12 weeks. Planned start Jun 2019; status: withdrawn.
02
Drugs
SPARC0913
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03927443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927443.